Phosphorus lowering treatments in chronic kidney disease
Pro Research Analysisby 
Searched over 200M research papers
Phosphorus Lowering Treatments in Chronic Kidney Disease: Efficacy and Safety
Importance of Phosphorus Control in CKD
Managing serum phosphorus is crucial in chronic kidney disease (CKD) because high phosphorus levels are linked to vascular calcification, cardiovascular disease, and increased mortality. Despite advances in treatment, controlling phosphorus remains challenging, especially in advanced CKD stages, and the optimal target range for serum phosphorus is still debated .
Phosphate Binders: Types and Comparative Efficacy
Phosphate binders are the mainstay of phosphorus-lowering therapy in CKD. Common agents include sevelamer, lanthanum, calcium-based binders, iron-based binders, magnesium carbonate, colestilan, bixalomer, and nicotinamide 123.
- Efficacy: All phosphate binders effectively lower serum phosphorus compared to placebo. Among these, magnesium carbonate and iron-based binders (like ferric citrate) show the strongest phosphorus-lowering effects 23. Combination therapies and multidrug strategies often provide higher efficacy and safety .
- Sevelamer and Lanthanum: Both are effective in reducing serum phosphorus and are associated with lower risks of hypercalcemia compared to calcium-based binders 147. Sevelamer also improves lipid profiles and reduces hospitalization rates 47.
- Iron-Based Binders: Iron-based binders, such as ferric citrate, not only lower phosphorus effectively but also have better acceptability, with fewer treatment withdrawals .
- Nicotinamide: Nicotinamide is as effective as sevelamer in lowering phosphorus but is less well tolerated, with higher rates of adverse events and treatment discontinuation 910.
Impact on Clinical Outcomes
- Mortality and Cardiovascular Events: There is no clear evidence that phosphate binders reduce all-cause or cardiovascular mortality compared to placebo. However, sevelamer and lanthanum may reduce all-cause mortality compared to calcium-based binders 14.
- Biochemical and Laboratory Outcomes: Phosphate binders improve several laboratory parameters, including serum phosphate, calcium, coronary artery calcium scores, and lipid profiles. However, their effect on parathyroid hormone and bone mineral density is less clear .
- Vascular Calcification: Lowering phosphorus, especially with agents like lanthanum, may help prevent vascular calcification, possibly through effects on fibroblast growth factor 23 (FGF23) .
Dietary Phosphorus Restriction
Dietary phosphorus restriction can reduce phosphorus absorption and urinary excretion, but short-term interventions may not significantly lower FGF23 levels in CKD patients. Longer-term strategies may be needed for meaningful changes in FGF23 .
Safety and Tolerability
- Adverse Events: Sevelamer is associated with constipation, lanthanum with nausea, and iron-based binders with diarrhea. Calcium-based binders carry a higher risk of hypercalcemia 147.
- Patient Acceptability: Ferric citrate stands out for its lower dropout rates, indicating better patient acceptability . Nicotinamide, while effective, is less tolerated due to side effects like thrombocytopenia 910.
Ongoing Challenges and Future Directions
Despite the availability of multiple phosphate-lowering agents, hyperphosphatemia remains common in advanced CKD, and the impact of these treatments on long-term clinical outcomes is still uncertain. More large-scale, well-designed studies are needed to clarify the benefits of phosphorus reduction on morbidity and mortality in CKD 16.
Conclusion
Phosphorus-lowering treatments, especially phosphate binders, are effective in reducing serum phosphorus in CKD patients. Magnesium carbonate and iron-based binders show strong efficacy, while sevelamer and lanthanum offer additional safety benefits over calcium-based binders. However, the effect of these treatments on long-term clinical outcomes remains unclear, and patient tolerability varies among agents. Dietary management and combination therapies may further enhance phosphorus control, but ongoing research is needed to optimize treatment strategies in CKD.
Sources and full results
Most relevant research papers on this topic
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Phosphate-binder treatment does not reduce mortality or cardiovascular events in adults with chronic kidney disease, but iron-based binders show potential for greater phosphate lowering.
A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials
SL + CT is the most recommended treatment strategy for hyperphosphatemia in chronic kidney disease patients, with multidrug combination strategies generally having a higher efficacy and safety profile.
The challenge of controlling phosphorus in chronic kidney disease.
Controlling serum phosphorus in chronic kidney disease is crucial for improving clinical outcomes, but achieving a specific level-range remains challenging.
DOI
Sevelamer Treatment for Hyperphosphatemia in a Saudi Arabian Chronic Renal Disease Patient
Sevelamer effectively lowers serum phosphorus levels in dialysis patients while improving lipid profiles, making it a valuable therapeutic option for managing hyperphosphatemia in chronic kidney disease patients.
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
Dietary phosphorus restriction and lanthanum can lower urinary phosphate excretion, but reducing FGF23 levels in chronic kidney disease patients may require longer interventions than in healthy volunteers.
DOI
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.
Nicotinamide (NAM) and sevelamer (SEV) are equally effective in lowering serum phosphorus in chronic kidney disease patients, but NAM's tolerance is significantly inferior to SEV, with extremely high 2PY levels potentially contributing to its side effects.
DOI